Soluble PD-1 but Not PD-L1 Levels Predict Poor Outcome in Patients with High-Risk Diffuse Large B-Cell Lymphoma.
diffuse large B-cell lymphoma
soluble PD-1
soluble PD-L1
survival
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
22 Jan 2021
22 Jan 2021
Historique:
received:
29
12
2020
revised:
17
01
2021
accepted:
18
01
2021
entrez:
27
1
2021
pubmed:
28
1
2021
medline:
28
1
2021
Statut:
epublish
Résumé
Interaction of checkpoint receptor programmed death 1 (PD-1) with its ligand 1 (PD-L1) downregulates T cell effector functions and thereby leads to tumor immune escape. Here, we aimed to determine the clinical significance of soluble PD-1 (sPD-1) and soluble PD-L1 (sPD-L1) in patients with diffuse large B-cell lymphoma (DLBCL). We included 121 high-risk DLBCL patients treated in the Nordic NLG-LBC-05 trial with dose-dense immunochemotherapy. sPD-1 and sPD-L1 levels were measured from serum samples collected prior to treatment, after three immunochemotherapy courses, and at the end of therapy. sPD-1 and sPD-L1 levels were the highest in pretreatment samples, declining after three courses, and remaining low post-treatment. Pretreatment sPD-1 levels correlated with the quantities of PD1+ T cells in tumor tissue and translated to inferior survival, while no correlation was observed between sPD-L1 levels and outcome. The relative risk of death was 2.9-fold (95% CI 1.12-7.75,
Identifiants
pubmed: 33499013
pii: cancers13030398
doi: 10.3390/cancers13030398
pmc: PMC7865236
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Ida Montinin Säätiö
ID : -
Organisme : Suomen Onkologiayhdistys
ID : -
Organisme : Helsingin ja Uudenmaan Sairaanhoitopiiri
ID : -
Organisme : Helsingin Yliopisto
ID : -
Organisme : Academy of Finland
ID : -
Organisme : A.P. Moeller Foundation
ID : -
Organisme : Danish Lymphoma Group
ID : -
Organisme : Oticon Fonden
ID : -
Organisme : Danmarks Frie Forskningsfond
ID : -
Organisme : Karen Elise Jensens Fond
ID : -
Organisme : Aarhus Universitet
ID : -
Organisme : Aarhus Universitetshospital
ID : -
Organisme : Syöpäjärjestöt
ID : -
Organisme : Sigrid Juséliuksen Säätiö
ID : -
Organisme : Nordic Cancer Union
ID : -
Références
Cancer Sci. 2018 Jun;109(6):1753-1763
pubmed: 29675979
Cancer Sci. 2018 Aug;109(8):2435-2445
pubmed: 29890018
Immunity. 2018 Mar 20;48(3):434-452
pubmed: 29562194
Scand J Rheumatol. 2014;43(2):101-8
pubmed: 24182347
Lancet Haematol. 2015 Oct;2(10):e445-55
pubmed: 26686046
Cell Immunol. 2005 Jun;235(2):109-16
pubmed: 16171790
Mod Pathol. 2019 Jun;32(6):741-754
pubmed: 30666052
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Ann Oncol. 2018 Dec 1;29(12):2363-2370
pubmed: 30307529
Blood. 2018 Jan 4;131(1):68-83
pubmed: 29118007
Clin Exp Med. 2018 Nov;18(4):505-512
pubmed: 29876769
Cancer Immunol Res. 2019 Apr;7(4):644-657
pubmed: 30745366
Nat Med. 2018 May;24(5):679-690
pubmed: 29713087
Adv Ther. 2017 Oct;34(10):2232-2273
pubmed: 28983798
Blood. 2019 May 23;133(21):2279-2290
pubmed: 30910787
N Engl J Med. 2018 Apr 12;378(15):1396-1407
pubmed: 29641966
Leukemia. 2014 Dec;28(12):2367-75
pubmed: 24732592
Cytokine. 2011 Nov;56(2):231-8
pubmed: 21733718
Leukemia. 2017 Apr;31(4):988-991
pubmed: 28035137
Oncoimmunology. 2017 Mar 31;6(5):e1310358
pubmed: 28638732
Blood. 2015 Nov 5;126(19):2193-201
pubmed: 26239088
Cancer Med. 2016 Nov;5(11):3077-3084
pubmed: 27709793
Cancer Immunol Immunother. 2019 Mar;68(3):407-420
pubmed: 30564890
Haematologica. 2019 Feb;104(2):338-346
pubmed: 30237271
Front Immunol. 2016 Dec 12;7:550
pubmed: 28018338
BMC Cancer. 2020 Feb 13;20(1):120
pubmed: 32054467
Cancer Immunol Immunother. 2019 Mar;68(3):353-363
pubmed: 30506460
Elife. 2019 Nov 15;8:
pubmed: 31729316
Cell. 2017 Oct 5;171(2):481-494.e15
pubmed: 28985567
J Clin Oncol. 2019 Feb 20;37(6):481-489
pubmed: 30620669
J Immunol. 2006 Dec 15;177(12):8844-50
pubmed: 17142787
Blood. 2020 Feb 20;135(8):523-533
pubmed: 31790142
Am J Hematol. 2013 Apr;88(4):273-6
pubmed: 23460351
Cancer Immunol Immunother. 2019 Mar;68(3):421-432
pubmed: 30564891
J Immunother. 2011 Apr;34(3):297-306
pubmed: 21389868
Blood Adv. 2020 May 12;4(9):1906-1915
pubmed: 32380536
J Biol Chem. 2013 Apr 26;288(17):11771-85
pubmed: 23417675
Hematol Oncol. 2018 Oct;36(4):709-712
pubmed: 30146693
Cancer Cell. 2017 Jun 12;31(6):848-848.e1
pubmed: 28609660
Haematologica. 2020 Feb 20;:
pubmed: 32079690